Tumours also develop resistance to cytotoxic T-cell killing by creating a defective antigen presentation pathway through the down-regulation of MHC molecules, transporter associated with antigen processing protein (TAP), and the tumour antigen itself. The gene discussed is HLA-C; the disease is neoplasm.